Breaking News, Financial News

Financial Report: WuXi PharmaTech 3Q10

Growth in the quarter was attributed to growth in Lab Services and Manufacturing Services.

WuXi PharmaTech 3Q10

3Q Revenues: $83.8 million (+20%)

3Q Earnings: $44.3 million (+209%)

YTD Revenues: $245.5 million (+25%)

YTD Earnings:
$73.5 million (+80%)

Comments: Growth in the quarter was attributed to growth in Lab Services and Manufacturing Services. China-based Lab Services revenues were up 19% in the quarter to $57.1 million. U.S Lab Services revenues increased 20% to $19.6 million. Manufacturing revenues were $7.1 million (+23%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters